InvestLog
Back to Market返回行情

KAPA Kairos Pharma, Ltd.

AMEXHealthcare
$0.3527-4.68%ClosedMarket Cap: $7.6M

As of 2026-07-10 15:59

Why KAPA matters now

Kairos Pharma, Ltd. (KAPA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.35 with -4.68% on the session and $7.6M in market capitalization.

The latest indexable market news headline is "All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy" from Zacks Investment Research.

Latest News

All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to BuyZacks Investment Research · 2026-07-02
Kapa Gold Announces the Results of Its 2026 Annual General MeetingNewsfile Corp · 2026-06-19
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to ShareholdersBusiness Wire · 2026-06-04
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical AwardBusiness Wire · 2026-05-14
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVINewsfile Corp · 2026-05-13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

AMEX

Beta

1.50

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.